- Home
- RRC vs LNTH Comparison
RRC vs LNTH Comparison
Compare RRC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRC
- LNTH
- Stock Information
- Founded
- RRC 1976
- LNTH 1956
- Country
- RRC United States
- LNTH United States
- Employees
- RRC N/A
- LNTH N/A
- Industry
- RRC Oil & Gas Production
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RRC Energy
- LNTH Health Care
- Exchange
- RRC Nasdaq
- LNTH Nasdaq
- Market Cap
- RRC 8.0B
- LNTH 7.5B
- IPO Year
- RRC N/A
- LNTH 2015
- Fundamental
- Price
- RRC $40.09
- LNTH $81.24
- Analyst Decision
- RRC Hold
- LNTH Strong Buy
- Analyst Count
- RRC 18
- LNTH 5
- Target Price
- RRC $42.41
- LNTH $133.80
- AVG Volume (30 Days)
- RRC 3.0M
- LNTH 1.4M
- Earning Date
- RRC 04-22-2025
- LNTH 05-07-2025
- Dividend Yield
- RRC 0.89%
- LNTH N/A
- EPS Growth
- RRC N/A
- LNTH N/A
- EPS
- RRC 1.11
- LNTH 3.53
- Revenue
- RRC $2,610,836,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- RRC $29.81
- LNTH $4.96
- Revenue Next Year
- RRC $11.52
- LNTH $10.25
- P/E Ratio
- RRC $36.14
- LNTH $23.00
- Revenue Growth
- RRC 12.00
- LNTH 12.53
- 52 Week Low
- RRC $27.29
- LNTH $74.34
- 52 Week High
- RRC $41.95
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- RRC 67.28
- LNTH 32.82
- Support Level
- RRC $39.64
- LNTH $77.01
- Resistance Level
- RRC $40.99
- LNTH $83.60
- Average True Range (ATR)
- RRC 0.97
- LNTH 3.77
- MACD
- RRC 0.71
- LNTH -2.21
- Stochastic Oscillator
- RRC 88.11
- LNTH 13.26
About RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.